Compare Crispr Therapeutics AG (CRSP) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs FTAI Aviation Ltd — how do they compare? Crispr Therapeutics AG trades at $53.2 (market cap $4.88B), while FTAI Aviation Ltd trades at $169.28 (market cap $17.57B). The key difference: FTAI Aviation Ltd is far larger — about 3.6× Crispr Therapeutics AG's market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and FTAI Aviation Ltd for 22 Days on average.
| CRSP | FTAI | |
|---|---|---|
Market Cap | $4.88B | $17.57B |
Volume | 2,861,747 | 1,905,014 |
Sector | Health | Industrials |
52-Week High | $74.92 | $310.04 |
52-Week Low | $44.34 | $152.80 |
Typical Hold Time | 77 Days | 22 Days |
Enterprise Value | $3.30B | $20.69B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
FTAI Aviation Ltd. (FTAI) trades at $169.13, down 3.26% over 24 hours, with a bearish technical signal from moving averages. Recent financials show strong revenue growth to $2.51B in 2025 and a net income margin of 15.94%, but earnings have missed expectations for three consecutive quarters. The company announced a $500 million share repurchase program and a strategic aircraft acquisition, signaling management confidence. Valuation ratios are elevated, with a P/E of 37.35 and P/B of 43.49, reflecting high growth expectations.
The outlook for FTAI is mixed; analyst consensus is unanimously bullish with a $321.25 price target, but near-term risks include earnings misses and negative operating cash flow. Long-term growth drivers include expansion in aerospace products and power segments, though execution risks and market volatility could pressure the stock. Investors should weigh strong institutional support against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
